Skip to main content

James F. Howard, Jr., MD – Presentations (September – November 2020)

James F. Howard, Jr, MD, presented via webcast:

Invited Lectures

  • Neurology Club, Department of Neuropsychiatry, “’Refractory’ Myasthenia Gravis: Hope for the Future.” University of Alexandria; Alexandria, Egypt; September
  • 11th Annual Myasthenia Gravis Health Care Professionals Education Virtual Conference, “The Expanding Universe of Myasthenia Gravis Therapeutics.” October
  • Neurology Grand Rounds, Oregon Health and Sciences University, “Complement Inhibition in Myasthenia Gravis; An Evolving Treatment Strategy.” October
  • MGFA New England Virtual Regional Conference, “Myasthenia Gravis: The Dawn of a Therapeutic Revolution.” October

Presentations at Meetings

  • “Safety of eculizumab in NMOSD and MG – analysis of the phase 3 studies PREVENT and REGAIN and their extensions.”  MSVirtual2020, September (Co-author)
  • “Generalized myasthenia gravis: complement and the neuromuscular junction.” Industry forum on “Complement activation in neurological diseases: from the central nervous system to the neuromuscular junction.” International Congress on Neuromuscular Diseases Digital Program (ICNMDigital), September (Co-author)
  • “Treatment impact on specific symptom MG-ADL domains in myasthenia gravis patients: Phase 2 efgartigimod study analysis.” International Congress on Neuromuscular Diseases Digital Program (ICNMDigital), September (Co-authored with Manisha Chopra, MBBS, and others)
  • “ADAPT: A phase 3 study of the FcRn antagonist, efgartigimod, in generalized myasthenia gravis.” 2020 Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine, October (Co-authored with Manisha Chopra, MBBS, and others)
  • Dr. Howard gave five presentations at the 2020 Annual Scientific Session of the Myasthenia Gravis Foundation of America in October.

2020 Annual Scientific Session of the Myasthenia Gravis Foundation of America in October: 

  • “Covid-19 Associated Risks and Effects in Myasthenia Gravis (Care-Mg): An International Physician-Reported Registry.” (Co-author)
  • “Treatment of patients with myasthenia gravis with efgartigimod: results of the Phase 3 ADAPT study.” (Co-authored with Manisha Chopra, MBBS, and others)
  • “The Myasthenia Gravis Inebilizumab Trial (Mint): Design of Randomized, Placebo-Controlled Phase 3 Study of an Anti-Cd19 Monoclonal Antibody in Generalized Myasthenia Gravis.” (Co-author)
  • “Two-year post-marketing safety experience of eculizumab in patients with generalized myasthenia gravis. (Co-author)
  • A case of MuSK myasthenia gravis presenting with isolated respiratory insufficiency.  (Co-authored with Carolyn Tsai, MD, Anahit Mehrabyan, MD, and others)